The pharmaceutical industry is increasingly looking to genomics-based drug discovery to supply the numbers of new agents needed for companies' growth and survival. In the field of cardiovascular disease (CVD) in particular, where the market for statins, antihypertensives, and other major drugs is relatively mature, new and different therapeutic concepts are needed. Research into understanding of the mechanistic basis of atherosclerosis and its complications focuses on two key areas: endothelial cell biology and inflammation. Most of these efforts are in the research stage, but several drug candidates have reached the preclinical or clinical stage, with some novel compounds close to market entry.

Next-Generation Cardiovascular Therapeutics, a Decision Resources, Inc., report, discusses the following topics:

  -- The emerging paradigm of the pathophysiology of cardiovascular disease.   -- Current therapies and market dynamics.   -- Late-stage therapies.   -- Key biopharmaceutical companies' market position.   -- The future of CVD therapeutics.  

In addition, Next-Generation Cardiovascular Therapeutics profiles eight biopharmaceutical companies: Actelion, Cor Therapeutics, CV Therapeutics, Interleukin Genetics, Millennium Pharmaceuticals, Scios, Texas Biotechnology, and 3-Dimensional Pharmaceuticals. A detailed chapter devoted to each company reports on significant alliances, patent positions, and developmental pipelines and provides competitive assessments.

Next-Generation Cardiovascular Therapeutics is a DR Reports publication from Decision Resources, Inc. This report is available for $4,250.00.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, +1-781-296-2553,

Shire Pharmaceuticals Will Combat Generic Competition with Adderall XR, a Long-Acting Reformulation of Its Attention-Deficit/Hyperactivity Disorder Drug, According to a Decision Resources Study

View Now